Romero-Guadarrama MB, Hernández-González MM, Durán- Padilla MA, Mandujano- Álvarez G, Alcántara-Vásquez A

Language: Spanish
References: 21
Page: 192-198
PDF size: 176.15 Kb.

ABSTRACT

The diffuse large B cell lymphomas (DLBCL) is an heterogeneous group of lymphoid neoplasms, defined as a proliferation of cells with a nuclear size equal or slightly larger than a macrophage or twice the size of normal lymphocyte (WHO classification of 2001). The present is a descriptive and retrospective work. The objective was to analyze the histological subtypes and the expression of different immunohistochemical markers. In the material studied DLBCL makes up 59.4% of all hematological neoplasias. The average age in 148 patients with DLBCL was 50 years and the male sex was predominantely affected (male female ratio 58-42%). The clinical stages of most patients at the time of diagnosis were II and III and 58% had constitutional B symptoms. The DLBCL is predominately found in lymph nodes (59.4%) and the rest (40.5%) have extranodal involvement, most frequently in the Waldeyer ring, centrofacial structures, digestive tract, skin, soft tissues, bones, central nervous system and other sites. Three patients were seropositive for HIV. The most common variant was the centroblastic lymphoma, both in lymph nodes (80%) and extranodal sites (98.3%). Most DLBCL was positive for CD 20 (97.9%) and other pan B markers. The positivity for bcl 2 was 38.5% for those with lymph node involvement and 38.3% or the extranodal ones. For bcl 6 the expression was 20.9% in the ones affecting the lymph nodes and 18.3% in the cases with extranodal involvement. None of these cases showed positivity for CD 5 or ALK. In conclusion DLBCL was the type of non Hodgkin lymphoma (NHL) more frequent, the average age was 50 years, 17 years more youngs that patients with the same type of non Hodgkin lymphoma of the development countrys, the most common variant was the centroblastic and the extranodal site more frequent was centrofacial structures.

REFERENCES

1. Frenk-Mora J, Ruelas-Barajas E, Tapia-Conyer R, Castañón-Romo R et al. Compendio de Cáncer 2000/Mortalidad/Morbilidad. Registro Histopatológico de Neoplasias Malignas. Dirección General de Epidemiología. www.epi.org.mx

2. National Cancer Institute. Summary and description of a working formulation for clinical usage. The non-Hodgkin´s Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.

3. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.

4. Ioachim HL, Dorsett B, Cronin W et al. Acquired immunodeficiency syndrome-associated lymphomas: Clinical, pathologic, immunologic, and viral characteristics of 111 cases. Human Pathol 1991; 22: 659-673.

5. Jaffe ES, Harris LN, Stein H, Vardiman WJ et al. Tumours of haematopoietic and lymphoid tissues. Pathology and genetics. Lyon: IARC Press, 2001; 171-187.

6. Feller AC, Diebold J. Histopathology of nodal and extranodal non-Hodgkin´s lymphomas. Based on the WHO Classification. 3rd ed. Berlin Heidelberg: Springer-Verlag, 2004; 75-99.

7. Hsu FJ, Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 1995; 86: 3072-3082.

8. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.

9. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large. B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.

10. Lossos IS, Okada CY, Tibshirani R, Warnke R, Vose J, Greiner T, Levy R. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95: 1797-1803.

11. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, Staudt LM, Levy R. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97 (10): 209-10.213.

12. Ohshima K, Kawasaki C, Muta H et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-162.

13. Berglund M, Thunberg U, Amini R-M et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology 2005; 18: 1113-1120.

14. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using microarray. Blood 2003; 103: 275-282.

15. Hembury TA, Lee B, Gascoyne DR, Macpherson NL, Yang B, House N, Medeiros Jeffrey L, His DE. Primary Cutaneous Diffuse large B-cell lymphoma. A clinicopathologic study of 15 cases. Am J Clin Pathol 2002: 117: 574-580.

16. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin´s lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer 1997; 923-930.

17. Diebold J Anderson JR, Armitage JO, Connors J, MacLennan KA, Müller-Hermelink HK et al. For the non-Hodgkin´s lymphoma classification project (2002) Diffuse large B-cell lymphoma: A clinicopathologic analysis of 444 cases classified according to the up-dated Kiel classification. Leukemia Lymphoma 2002: 43: 97-104.

18. Kuze T, Nakamura N, Hahimoto Y, Abe M, Wakasa H. Clinicopathological, immunological and genetic studies of CD 30 anaplastic large cel lymphoma of B-cell type: Association with Epstein-Barr virus in a Japanese population. J Pathol 1996; 180: 236-242.

19. Delecluze HJ, Hummel M, Marafioti T, Anagnostopoulos I, Stein H. Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern. J Pathol 1999: 188; 133-138.

20. Ramsay AD, Smith WJ, Issacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988: 12; 433-443.

21. Oshima K, Masuda Y, Kikuchi M, Sumiyoshi Y, Kobari S, Yoneda S, Takeshita M, Kimura N. Monoclonal B cells and restricted oligoclonal T cells in T-cell-rich B-cell lymphoma. Pathol Res Pract 1994: 190; 15-24.